Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Non-Current Assets: 2023-2025

Historic Non-Current Assets for CG Oncology (CGON) over the last 2 years, with Sep 2025 value amounting to $34.1 million.

  • CG Oncology's Non-Current Assets rose 8627.11% to $34.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.1 million, marking a year-over-year increase of 8627.11%. This contributed to the annual value of $587,000 for FY2024, which is 88.66% down from last year.
  • As of Q3 2025, CG Oncology's Non-Current Assets stood at $34.1 million, which was up 20.09% from $28.4 million recorded in Q2 2025.
  • Over the past 5 years, CG Oncology's Non-Current Assets peaked at $34.1 million during Q3 2025, and registered a low of $391,000 during Q3 2024.
  • Over the past 3 years, CG Oncology's median Non-Current Assets value was $2.9 million (recorded in 2023), while the average stood at $12.1 million.
  • As far as peak fluctuations go, CG Oncology's Non-Current Assets slumped by 88.66% in 2024, and later spiked by 8,627.11% in 2025.
  • CG Oncology's Non-Current Assets (Quarterly) stood at $5.2 million in 2023, then plummeted by 88.66% to $587,000 in 2024, then surged by 8,627.11% to $34.1 million in 2025.
  • Its Non-Current Assets was $34.1 million in Q3 2025, compared to $28.4 million in Q2 2025 and $27.0 million in Q1 2025.